Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Target Selector BRAF RUO Kits

Biocept has launched a Target Selector research-use-only molecular assay for the detection of BRAF mutations in both formalin-fixed, paraffin-embedded samples and blood samples. The kits use the company's Switch-Blocker technology to enrich the specimen for mutations of interest, resulting in ultra-high assay sensitivity and specificity. Biocept said that in general, its Target Selector kits can detect mutations of interest in circulating tumor DNA at a level of one mutant copy in 10,000 wildtype molecules. The assays can be used with a variety of analytical platforms including qPCR, Sanger sequencing, next generation sequencing, microarrays, and mass spectrometry. The new BRAF kit complements the company's previously launched EGFR mutation-detection assay.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.